Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In-vitro genetic modification of mitochondrial function.

R W Taylor1, P F Chinnery, D M Turnbull

  • 1Department of Neurology, The Medical School, University of Newcastle upon Tyne, UK. r.w.taylor@ncl.ac.uk

Human Reproduction (Oxford, England)
|October 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depression, anxiety and PTSD symptoms before and during the COVID-19 pandemic in the UK.

Psychological medicine·2022
Same author

Neuropathological and biochemical investigation of Hereditary Ferritinopathy cases with ferritin light chain mutation: Prominent protein aggregation in the absence of major mitochondrial or oxidative stress.

Neuropathology and applied neurobiology·2020
Same author

Inheritance of mitochondrial DNA in humans: implications for rare and common diseases.

Journal of internal medicine·2020
Same author

Systematic review of cognitive deficits in adult mitochondrial disease.

European journal of neurology·2019
Same author

Design and baseline characteristics of the Biomarkers Of Risk In Colorectal Cancer (BORICC) Follow-Up study: A 12+ years follow-up.

Nutrition and health·2019
Same author

Correction: Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy-like disease.

Genetics in medicine : official journal of the American College of Medical Genetics·2019
Same journal

Characterizing endometriosis and adenomyosis symptom clusters and their impact on quality of life in the All of Us Research Program.

Human reproduction (Oxford, England)·2026
Same journal

A new regulatory framework: impact of the SoHO Regulation for medically assisted reproduction.

Human reproduction (Oxford, England)·2026
Same journal

Subfertility in relation to gestational weight gain and gestational diabetes: the Norwegian Mother, Father and Child Cohort Study.

Human reproduction (Oxford, England)·2026
Same journal

Pathogenic variants in ACTRT3 lead to male infertility characterized by fertilization defects.

Human reproduction (Oxford, England)·2026
Same journal

A large retrospective study on 1PN embryo transfer supports the need for updated harmonized best practice guidelines.

Human reproduction (Oxford, England)·2026
Same journal

Explainability of artificial intelligence (AI) tools in assisted reproductive technologies (ARTs): promise, clinical reality, and conceptual limits.

Human reproduction (Oxford, England)·2026
See all related articles

Researchers propose using peptide nucleic acids (PNAs) to target and inhibit mutant mitochondrial DNA (mtDNA) replication. This approach aims to selectively propagate healthy mtDNA, potentially correcting defects and halting disease progression in incurable mitochondrial disorders.

Area of Science:

  • Mitochondrial genetics
  • Molecular medicine
  • Genetic disease therapy

Background:

  • Mitochondrial DNA (mtDNA) defects cause incurable, progressive diseases.
  • Heteroplasmy, a mix of mutant and wild-type mtDNA, underlies disease expression above a critical threshold.

Purpose of the Study:

  • To investigate the therapeutic potential of sequence-specific antigenomic peptide nucleic acids (PNAs).
  • To develop a strategy for selectively inhibiting mutant mtDNA replication and promoting wild-type mtDNA propagation.

Main Methods:

  • Utilizing sequence-specific antigenomic PNAs to hybridize and inhibit mutant mtDNA replication.
  • Employing a nuclear-encoded mitochondrial targeting sequence for PNA import into mitochondria.
  • In vitro and cell culture experiments to assess PNA efficacy and mitochondrial uptake.

Related Experiment Videos

Main Results:

  • Demonstrated cellular uptake of PNA molecules.
  • Confirmed PNA import into mitochondria via a targeting sequence.
  • Established the feasibility of inhibiting mutant mtDNA replication.

Conclusions:

  • Antigenomic PNAs show promise for treating mtDNA disorders by selectively eliminating mutant mtDNA.
  • This strategy could correct cellular defects and prevent disease progression.
  • Potential application to mtDNA deletion disorders is under consideration.